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We have taken a new approach to the identification of E2F-regulated promoters. After modification of a
chromatin immunoprecipitation assay, we cloned nine chromatin fragments which represent both strong and
weak in vivo E2F binding sites. Further characterization of three of the cloned fragments revealed that they are
bound in vivo not only by E2Fs but also by members of the retinoblastoma tumor suppressor protein family
and by RNA polymerase II, suggesting that these fragments represent promoters regulated by E2F transcrip-
tion complexes. In fact, database analysis indicates that all three fragments correspond to genomic DNA
located just upstream of start sites for previously identified mRNAs. One clone, ChET 4, corresponds to the
promoter region for beclin 1, a candidate tumor suppressor protein. We demonstrate that another of the clones,
ChET 8, is strongly bound by E2F family members in vivo but does not contain a consensus E2F binding site.
However, this fragment functions as a promoter whose activity can be repressed by E2F1. Finally, we demon-
strate that the ChET 9 promoter contains a consensus E2F binding site, can be activated by E2F1, and drives
expression of an mRNA that is upregulated in colon and liver tumors. Interestingly, the characterized ChET
promoters do not display regulation patterns typical of known E2F target genes in a U937 cell differentiation
system. In summary, we have provided evidence that chromatin immunoprecipitation can be used to identify
E2F-regulated promoters which contain both consensus and nonconsensus binding sites and have shown that
not all E2F-regulated promoters show identical expression profiles.
The E2F family consists of six E2Fs which heterodimerize
with one of two different DP proteins to create 12 different
DNA binding transcriptional regulators (7, 9). The E2F factors
can be divided into three subgroups: (i) E2F1, E2F2, and
E2F3, which are highly related and display maximal expression
in late G1 to early S phases; (ii) E2F4 and E2F5, which are less
responsive to changes in proliferation and lack an N-terminal
domain contained within E2Fs 1 to 3; and (iii) E2F6, a recently
cloned E2F family member that lacks both the N-terminal
region common to E2Fs 1 to 3 and the C-terminal transacti-
vation domain common to E2Fs 1 to 5. Known E2F target
genes include those for critical cell cycle regulators (e.g., cy-
clins, Cdks, and Cdk inhibitors), as well as important mediators
of DNA synthesis (e.g., DNA polymerase alpha, DHFR, and
thymidine kinase). Genes controlled by E2F show low pro-
moter activity in quiescent and early G1 phase cells and high
promoter activity in late G1 and S phase cells. Many studies
have shown that the E2Fs can also bind to the pocket proteins
retinoblastoma protein (Rb), p107, and p130, and it is believed
that the interactions between the pocket proteins and the E2Fs
are critical in E2F-mediated cell cycle regulation of transcrip-
tion (7).
Several lines of evidence suggest that proper regulation of
E2F target genes is critical to maintain normal cell prolifera-
tion. For example, many human tumors have suffered muta-
tions in the regulators of E2F activity, suggesting that loss of
E2F target gene regulation contributes to neoplastic transfor-
mation. Also, we and others have shown that overexpression of
E2Fs has severe consequences in both normal and neoplasti-
cally transformed cells (19, 23, 24, 37, 40, 51). Studies such as
these suggest that deregulation of certain E2F target genes is
detrimental to proper cell growth control. E2F family members
have been reported to bind to and regulate approximately 30
different target genes. However, the fact that E2F overexpres-
sion can have severe biological consequences without large
changes in expression of these known target genes (reference
24 and unpublished data) suggests that E2F factors may reg-
ulate a set of target genes that have not been previously iden-
tified by the candidate gene approach. In fact, a recent mi-
croarray study suggested that hundreds of genes are affected by
the overexpression of E2Fs (31), but the exact role E2F plays
in the regulation of these genes needs to be examined in more
detail.
Recently, a computer analysis of promoter databases was
used to search for new E2F-regulated promoters (21). This
study suggested that approximately 7% of mammalian promot-
ers may be regulated by E2F factors. However, our previous
approach had two main limitations. First, only previously char-
acterized promoters are present in the current databases;
therefore, promoters for as-yet-uncharacterized genes cannot
be analyzed. Second, the computer-assisted approach was
based on screening for sequences having high homology to the
E2F consensus site. This consensus site was developed using a
small subset of E2F binding sites identified in cell cycle-regu-
lated promoters. If E2Fs bind to additional sites, either alone
or in cooperation with other DNA binding proteins, these sites
would be overlooked in the database search. Therefore, it
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seems clear that it is necessary to take an unbiased approach to
identify additional E2F target genes. Accordingly, we have
used a modification of a chromatin immunoprecipitation assay
to clone novel E2F binding sites, most of which do not have
strong homology to the E2F consensus site developed using
cell cycle-regulated promoters. Interestingly, characterization
of several of these novel E2F binding promoters revealed
unique gene expression profiles.
MATERIALS AND METHODS
Cell culture and promoter and mRNA analyses. HeLa cells were grown in 50%
alpha minimal essential medium and 50% Joklik’s medium with 5% supplemen-
tal calf serum (HyClone) and 1% penicillin-streptomycin (Gibco). The cells were
grown to a density of 2  105 to 5  105 per ml before being harvested for
cross-linking experiments. For all chromatin immunoprecipitation experiments
presented in this study, asynchronously growing HeLa cells were used. For
analysis of transcriptional properties of the ChET (for chromatin-precipitated
E2F target) 8 promoter, a fragment was obtained by PCR using primers having
sequences complementary to the 477 to  94 region of the ChET 8 promoter
plus restriction sites. The ChET 9 promoter studies were performed with a
293-bp segment of the ChET 9 clone. The PCR fragment was digested and
inserted in either orientation into the HindIII site in pGL2 basic (Promega). For
analysis of promoter activity and responsiveness to E2F1, NIH 3T3 cells (Amer-
ican Type Culture Collection) were maintained and transfected as described
previously (14). pCMVE2F1 and the control vector pcDNA3 were described
previously (25). U937 cells were maintained and RNA was prepared as described
previously (8). Human tissue was procured at the University of Wisconsin Sur-
gical Pathology Department; as required by our institutional review board pro-
tocol, the identities of the patients were unknown. The excess tissue was frozen
after surgery, stored at 70°C, and prepared as described previously (11). Re-
verse transcription (RT)-PCR analyses were performed as described previously
(11). Details of the primers used and the required hybridization temperatures
can be found on our website at http://mcardle.oncology.wisc.edu/farnham. All
primers were synthesized at the University of Wisconsin Biotechnology Center.
Chromatin immunoprecipitation. Formaldehyde (Fisher Scientific) was added
at a final concentration of 1% directly to cell culture media of nonadherent
log-phase HeLa cells. Fixation proceeded at 22°C for 10 min and was stopped by
the addition of glycine to a final concentration of 0.125 M. The HeLa cells were
collected by centrifugation and rinsed in cold phosphate-buffered saline. The cell
pellets were resuspended in swelling buffer (10 mM potassium acetate, 15 mM
magnesium acetate, 0.1 M Tris [pH 7.6], 0.5 mM phenylmethylsulfonyl fluoride,
and 100 ng of leupeptin and aprotinin/ml), incubated on ice for 20 min, and then
Dounce homogenized. The nuclei were collected by microcentrifugation and
then resuspended in sonication buffer (1% sodium dodecyl sulfate, 10 mM
EDTA, 50 mM Tris-HCl [pH 8.1], 0.5 mM phenylmethylsulfonyl fluoride, and
100 ng of leupeptin and aprotinin/ml) and incubated on ice for 10 min. Prior to
sonication, 0.1 g of glass beads (212- to 300-m diameter; Sigma) was added to
each sample. The samples were sonicated on ice with an Ultrasonics sonicator at
setting 10 for six 20-s pulses to an average length of approximately 1,000 bp and
then microcentrifuged. The chromatin solution was precleared with the addition
of Staphylococcus aureus protein A-positive cells for 15 min at 4°C. Prior to use,
the Staph A cells were blocked with 1 g of sheared herring sperm DNA/l and
1 g of bovine serum albumin/l for at least 4 h at 4°C. Precleared chromatin
from 107 cells was incubated with 1 g of affinity-purified rabbit polyclonal
antibody or no antibody and rotated at 4°C for approximately 12 to 16 h.
Antibodies used included E2F1 no. 05-379 (UBI), E2F2 C-20 no. SC-633X
(Santa Cruz), E2F3 C-18 no. SC-878X (Santa Cruz), E2F4 C-20 no. SC-866X
(Santa Cruz), E2F5 E-19 no. SC999X (Santa Cruz), E2F6 E-20 no. SC-8366
(Santa Cruz), RNA polymerase II (a gift from David Bentley), p107 C-18 no.
SC318X, p130 C-20 no. SC 317X, and Rb C-15 no. SC-50X. Immunoprecipita-
tion, washing, and elution of immune complexes was carried out as previously
described (3). Prior to the first wash, 20% of the supernatant from the reaction
with no primary antibody for each time point was saved as total input chromatin
and was processed with the eluted immunoprecipitates beginning at the cross-
link reversal step. Cross-links were reversed by the addition of NaCl to a final
concentration of 200 mM, and RNA was removed by the addition of 10 g of
RNase A per sample followed by incubation at 65°C for 4 to 5 h. The samples
were then precipitated at 20°C overnight by the addition of 2.5 volumes of
ethanol and then pelleted by microcentrifugation. The samples were resus-
pended in 100 l of Tris-EDTA (pH 7.5), 25 l of 5 proteinase K buffer (1.25%
sodium dodecyl sulfate, 50 mM Tris [pH 7.5], and 25 mM EDTA), and 1.5 l of
proteinase K (Boehringer Mannheim) and incubated at 45°C for 2 h. Samples
were extracted with phenol-chloroform-isoamyl alcohol (25:24:1) followed by
extraction with chloroform-isoamyl alcohol and then precipitated with 1/10 vol-
ume of 3 M NaOAc (pH 5.3), 5 g of glycogen, and 2.5 volumes of ethanol. The
pellets were collected by microcentrifugation, resuspended in 30 l of H2O, and
analyzed by PCR. A detailed protocol can be found at http://mcardle.oncology
.wisc.edu/farnham.
PCR mixtures contained 2 l of immunoprecipitate or 2 l of a 1:100 dilution
of the total sample; 50 ng of each primer; 0.88 mM MgCl2; 0.2 mM (each) dATP,
dCTP, dGTP, and dTTP; 1 thermophilic buffer (Promega); and 1.25 U of Taq
DNA polymerase (Promega) in a total volume of 20 l. Following 32 to 35 cycles
of amplification, the PCR products were run on a 1.0% agarose gel and analyzed
by ethidium bromide staining. The PCR primers used to analyze target genes can
be found on our web site (http://mcardle.oncology.wisc.edu/farnham).
Cloning novel E2F targets. Several modifications of the chromatin immuno-
precipitation protocol were required for the cloning of novel target genes. The
first modification occurred at the elution step. Instead of eluting twice using 150
l of elution buffer each time, the immunoprecipitated chromatin was eluted
from the Staph A cells once, using 30 l of elution buffer. The eluate was then
diluted with 270 l of immunoprecipitation dilution buffer to a total volume of
300 l, and a new aliquot of the same antibody as that used in the first immu-
noprecipitation was added for an overnight incubation at 4°C. The next morning,
the samples were processed in the standard manner (i.e., they were washed and
eluted, cross-links were reversed, and the samples were proteinase K digested,
followed by phenol extraction and ethanol precipitation). At this point, an ali-
quot of the immunoprecipitated samples was used in a reaction with b-myb or
dhfr primers to demonstrate that E2F targets had been selected. The remaining
immunoprecipitated DNA was then treated with T4 DNA polymerase and
cloned into either the zero-blunt vector (Invitrogen) or HincII-digested puc 19.
Colonies having inserts were identified by restriction enzyme digestion using
enzymes in the polylinker. Plasmids having inserts greater than 500 bp were
chosen for further analysis. The sequence of each of the cloned fragments, details
concerning the sequences of the primers used to analyze each clone, the required
hybridization temperatures, and the product sizes can be found on our web site
(http://mcardle.oncology.wisc.edu/farnham). All primers were obtained at the
University of Wisconsin Biotechnology Center.
Electromobility shift assays. In vitro E2F DNA binding activity was assayed by
incubating about 6 g of HeLa nuclear extract with 2.5 g of sonicated salmon
sperm DNA and 2 l of 5X-500 buffer (100 mM HEPES [pH 7.4], 500 mM KCl,
5 mM MgCl2, 0.5 mM EDTA, 35% glycerol, and 5 mM NaF) in a total volume
of 18 l for 10 min at room temperature. Either a 34-bp double-stranded
oligonucleotide containing the E2F site from the b-myb promoter or a 22-bp
double-stranded oligonucleotide containing the E2F site from ChET 9 (both of
which were end labeled using T4 DNA kinase and [-32P]ATP as described
previously [28]) was then added in 2 l of water, and the incubation continued
for 20 min. The reactions were electrophoresed for 2 h on a 4% polyacrylamide
gel that had been preelectrophoresed for 30 min. When competition assays were
performed, the competitor DNA was included in the first incubation at a 50-fold
molar excess to the labeled probe.
RESULTS
In vivo isolation of E2F binding sites. Conventional target
gene identification methods, such as microarray analysis or
subtractive hybridization, examine changes in gene expression
profiles. Although valuable information can be obtained from
such studies, the disadvantage of using these techniques to
clone target genes of transcription factors is that the observed
changes may in fact be the result of indirect pathways influ-
encing gene expression patterns. For example, approximately
7% of the mRNAs on a human cDNA microarray responded
to overexpression of an E2F (31). However, promoter analyses
were not performed on these genes. Therefore it is not known
if the genes in that study are regulated by promoters that
contain consensus E2F binding sites or if the promoters are
directly bound by E2F. In contrast, one major advantage of
utilizing the chromatin immunoprecipitation method to iden-
tify novel target genes is that it selects for sites bound by the
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transcription factor of interest, thus eliminating the problem of
indirect effects. Therefore, we have chosen to use chromatin
immunoprecipitation as an unbiased approach to identify in
vivo E2F binding sites (Fig. 1A).
Briefly, following formaldehyde cross-linking of cells, chro-
matin is isolated and sheared to a desired length by sonication.
Immunoprecipitation proceeds with an antibody to a factor of
interest to selectively precipitate that protein and any DNA
fragment cross-linked to it. Thus, DNA sequence elements
associated with the desired protein in the context of the cellu-
lar environment are enriched in the immunoprecipitated sam-
ple. After reversal of the formaldehyde cross-links and purifi-
cation of the DNA, the precipitated DNA fragments are
cloned into a vector for isolation and further characterization
of factor binding sites and functional relevance. Although the
protocol for cloning E2F targets is similar to the standard
FIG. 1. (A) Schematic of the E2F chromatin immunoprecipitation cloning procedure. (B) Graphical representation of the results of a chromatin
immunoprecipitation experiment measuring E2F binding at the Myc promoter, Myc exon 2, and Hox3D exon 2. Scores representing homology to
the E2F consensus site as determined by computer analysis (21) are shown at the top of each graph. The y axis represents Imagequant quantitation
of the amount of specific PCR products expressed as the percentage of antibody binding versus the amount of PCR product obtained using a
standarized aliquot of input chromatin. The signal in the no-antibody lane was subtracted from each sample as a nonspecific binding background.
The E2F family members used in the immunoprecipitation are shown on the x axis.
6822 WEINMANN ET AL. MOL. CELL. BIOL.
 o
n
 January 15, 2014 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
chromatin immunoprecipitation assay that has been previously
described (3, 33, 49), several modifications were made to the
assay. Importantly, we performed two sequential chromatin
immunoprecipitations using the same antibody for both the
first and second steps. In preliminary studies, we found that a
large number of nonspecific fragments were cloned if only one
immunoprecipitation was performed. Therefore, the second
immunoprecipitation was used to decrease the amount of non-
specific DNA present to enable more efficient cloning of the
specific fragments. Also, a portion of the immunoprecipitated
samples was retained prior to cloning to analyze known target
genes as a positive control for the immunoprecipitation. Other
modifications important for cloning the immunoprecipitated
products can be found on our web site (http://mcardle.oncology
.wisc.edu/farnham).
Previous studies have demonstrated the validity of using the
chromatin immunoprecipitation protocol to identify site-spe-
cific interactions of transcription factors and promoter DNA in
the context of a living cell. Importantly, we have shown that
binding of E2F to target promoters is site specific. For exam-
ple, the chromatin immunoprecipitation assay has been used to
demonstrate that E2F4 binds with high affinity to the dhfr
promoter (which is known to be regulated by E2F) but does
not bind to the cad promoter (which is a Myc target gene) (3).
Also, in a previous report (49) we showed that a site-specific
mutation in the dhfr promoter eliminates binding of E2F4, as
monitored by the chromatin immunoprecipitation assay. In
addition, high-affinity binding of E2F family members to the
myc promoter is abolished when a point mutation is introduced
into the E2F site of that promoter (2). Finally, we have also
shown that E2Fs do not bind to promoters which are regulated
by liver-specific transcription factors (C. R. Graveel and P. J.
Farnham, unpublished data). Clearly, the chromatin immuno-
precipitation assay has been useful in demonstrating that not
all cellular promoters bind E2Fs and that those that do require
a specific site on the DNA for high-affinity in vivo binding.
However, we felt that additional controls were needed prior to
using this assay to clone novel targets. Namely, we wished to
clone regulatory E2F binding sites and not clone random,
nonfunctional E2F binding sites present in nonpromoter re-
gions of the genome. Previous analysis of promoter and exon 2
databases suggested that E2F sites are found at a much higher
frequency in promoters (21). However, sequences having high-
score matches to the E2F consensus site (scores of 0.86 or
better in the computer analysis) can be found in nonpromoter
regions as well. To explore whether E2F is bound to these sites
in living cells, we identified two such consensus sites located in
the second exon of the myc and the hox3D genes. Because the
myc promoter has previously been shown to be an E2F target
(30, 34, 50), we examined binding of E2F family members to
the exon sites in comparison to binding at the E2F site in the
Myc promoter. As shown in Fig. 1B, E2F binding to the myc
gene promoter is at much higher levels than binding to the myc
and hox3D exon 2 regions in the same chromatin sample, even
though the score match to the consensus E2F site is very high
in the exon 2 regions.
Having assured ourselves that the chromatin immunopre-
cipitation assay can be used to detect promoter-specific and
site-specific binding of E2F, we performed immunoprecipita-
tions from HeLa cell chromatin using antibodies against either
E2F1 or E2F4 and proceeded with the cloning procedure. We
chose clones having inserts of 500 bp or greater and examined
11 clones obtained by immunoprecipitation with the E2F1
antibody and 7 clones obtained by immunoprecipitation with
the E2F4 antibody for further analysis. The first step in the
characterization of the ChET clones was to determine which
ones contained bona fide E2F binding sites and which were
false positives.
Confirmation of E2F binding. In vitro assays may bias results
towards identifying sites which closely resemble the known
consensus E2F binding site. In addition, any large genomic
fragment may, by chance, contain a sequence resembling an
E2F site and be scored as a positive in an in vitro assay.
Therefore, we began confirmation of our cloned fragments
using an in vivo assay. The ChET clone inserts were sequenced,
and primers were made for use in chromatin immunoprecipi-
tation experiments. Because the E2F binding site could be
anywhere within the cloned fragment, primers were designed
to analyze both ends of each clone. HeLa chromatin was im-
munoprecipitated using antibodies to E2Fs 1 to 6; a no-anti-
body negative control was also performed (Fig. 2). As a posi-
tive control, binding of E2F family members to the dhfr
promoter was examined. For each primer set, a standardized
aliquot of the input chromatin (total) was also analyzed. The
ratio of the signals detected in the lanes containing samples
immunoprecipitated by the various antibodies to the signal
detected in the total lane allows a relative comparison repre-
senting the degrees of occupancy at the different sites. Figure
2 shows the results of a representative experiment using the
primer sets that showed the highest-affinity E2F binding for
each clone.
We began by testing the clones obtained using an E2F4
antibody in the immunoprecipitation step. Seven clones from
the E2F4 immunoprecipitation were analyzed for E2F binding
in vivo (Fig. 2). Of these, one clone (ChET 2) was found to be
present in samples in which no antibody was added to the
immunoprecipitation reaction mixture, indicating that binding
was nonspecific. The remaining six clones were all bound spe-
cifically by E2F family members in numerous independent
chromatin immunoprecipitation experiments. Although sev-
eral of these clones (e.g., ChET 1) were of modest affinity,
other clones (e.g., ChET 4) showed robust binding of E2Fs.
Eleven clones obtained by immunoprecipitation with an E2F1
antibody were also examined to determine whether they were
bound by E2Fs in vivo. We were unable to optimize primer sets
to four of these clones for analysis in subsequent chromatin
immunoprecipitation assays; these four clones will be included
in future studies if optimal primer sets can be empirically
determined. Therefore, we were left with seven clones for in
vivo analysis. We could not confirm binding of E2Fs to four of
these clones in subsequent chromatin immunoprecipitation as-
says; an example of one such false positive is shown below (see
Fig. 4, ChET 10). However, three of the seven E2F1 clones
contained bona fide E2F binding sites as determined by chro-
matin immunoprecipitation analysis. The ChET 8 and ChET 9
clones both contained high-affinity E2F binding sites in com-
parison to the binding detected at the well-characterized dhfr
promoter (Fig. 2). Binding to the third E2F1 clone was of
modest affinity (data not shown). In summary, of the 14 clones
that we were able to examine using in vivo assays (7 obtained
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using an E2F1 antibody and 7 obtained using an E2F4 anti-
body), 9 were confirmed to contain bona fide in vivo E2F
binding sites (Table 1). Although false positives are unavoid-
able, we believe that the two sequential immunoprecipitation
reactions greatly enriched for clones containing bona fide E2F
binding sites. It is important to note that the in vivo binding of
E2Fs to the ChET clones has been confirmed in numerous
experiments. For example, the experiments shown in Fig. 2 and
below (see Fig. 4) are completely independent from each other
and from the chromatin immunoprecipitation experiment used
to clone the fragments. We have also confirmed binding of
E2Fs to ChET 4, ChET 8, and ChET 9 in other human cell
types (data not shown).
Either an E2F1 or an E2F4 antibody was initially used for
the cloning procedure; however, we found that the cloned sites
did not reveal an E2F binding pattern to suggest family mem-
ber binding specificity. Rather, binding of multiple E2F family
members to each clone was detected in vivo (Fig. 2). These
results, suggesting a lack of DNA binding specificity among the
different E2Fs, are similar to those of our previous studies of
known E2F target genes (49). E2F family members contain a
highly conserved DNA binding domain; therefore, it is not
surprising that these family members have the ability to bind to
the same sequence in vivo. It is unlikely that our results indi-
cate that multiple E2F family members are simultaneously
binding to the same site, but the more likely explanation is that
a dynamic exchange occurs at a given site and various E2Fs are
trapped in different cells during the cross-linking procedure.
There are precedents for this hypothesis, as dynamic exchange
of the glucocorticoid receptor has been demonstrated in living
cells (29). With this in mind, it is worth noting that the cloned
sites can be separated into three basic categories. The first type
(e.g., ChET 9) showed an in vivo binding pattern very similar
FIG. 2. Confirmation of ChET clones by examining E2F binding in vivo. A representative chromatin immunoprecipitation experiment with
HeLa cells is shown. Immunoprecipitation proceeded utilizing antibodies (Ab) against E2F1 (lane 1), E2F2 (lane 2), E2F3 (lane 3), E2F4 (lane
4), E2F5 (lane 5), and E2F6 (lane 6) or no antibody (lane 8). Following DNA purification, samples were subjected to PCR with primers designed
for the individual E2F clones or the dhfr promoter as a control (labeled on the right). A portion of the total input was also examined by PCR (lane
7).
TABLE 1. Summary of ChET cloning
Parameter
Value
E2F4a E2F1a Total (%)
No. of fragments analyzed 7 7 14
No. of false positives 1 4 5 (36)
No. of clones specifically
bound by E2Fs
6 3 9 (64)
a Antibody to the indicated E2F was used to clone the fragments.
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to that of the dhfr promoter, i.e., strong binding of E2F1 to
E2F4 and very little binding of E2F5 or E2F6. The second type
(e.g., ChET 4 and ChET 8) showed strong binding of E2F1 to
E2F4 and little binding of E2F5 but detectable binding of
E2F6. Finally, the third type of site (e.g., ChET 1) showed
equal low-affinity binding of E2F1 to E2F6. The significance of
these distinct binding patterns is unknown, and further analysis
will be required to elucidate the functional consequences, if
any.
Genomic organization of ChET clones. We next analyzed
the sequences of the cloned fragments to determine if anything
was known about their identities. Three of the high-affinity
clones (ChET 4, ChET 8, and ChET 9) contained extremely
GC-rich sequences, which is a hallmark of many E2F-regulated
promoters. In addition, the PromoterInspector program (39)
detected a promoter region in ChET 9 and the CpG Promoter
program (15) detected a promoter-associated CpG island in
ChET 4 and ChET 8. Most E2F-regulated promoters have E2F
binding sites located in close proximity to the start site of
transcription (21). If our cloned fragments do, in fact, repre-
sent promoters, then it is possible that the sequences just
downstream of the E2F sites correspond to transcribed re-
gions. To test this hypothesis, we first identified the region of
the human genome corresponding to the cloned fragments and
then compared several kilobases of sequence on either side of
the cloned fragments to the GenBank database for a potential
cDNA match (Fig. 3). Interestingly, we found that a previously
identified but uncharacterized mRNA begins within the ChET
8 clone approximately 130 bp from one end. Also, a previously
uncharacterized mRNA begins within ChET 9 (although the
exact 5 end of this mRNA has not yet been determined).
Finally, the 5 end of the mRNA encoding Beclin 1, a candi-
date tumor suppressor protein, is contained within the ChET 4
clone.
In summary, it appears that the three high-affinity E2F bind-
ing sites all correspond to promoter regions: ChET 8 is the
promoter region for a 6,049-nt mRNA termed KIAA0254 (ac-
cession number D87443), which encodes a 1,009-amino-acid
protein with no homology to other known proteins; ChET 9 is
the promoter region for a 4,441-nt mRNA termed KIAA0160
(accession number D63881), which encodes an 803-amino-acid
protein having extensive homology to the Drosophila protein
Suppressor of zeste 12 [Su(z)12]; and ChET 4 is the promoter
for a 2,098-nt mRNA encoding Beclin 1 (accession number
AF139131), which is a candidate tumor suppressor gene. Of
the five remaining E2F4 ChET clones, four can be identified in
the human raw-sequence database. We have searched the
GenBank database using several kilobases of surrounding se-
quence but have not identified mRNAs associated with these
clones. Therefore, it is still unclear whether the remaining
E2F4 ChET clones correspond to promoter regions.
Characterization of the novel E2F binding sites. The next
step in the characterization of the ChET clones was to deter-
mine the compositions of the protein complexes recruited to
the clones in vivo. E2Fs bind directly to Rb, p107, and p130,
and we have previously shown that these proteins are compo-
nents of the transcription complexes formed on E2F target
promoters in vivo (49). E2Fs also bind to basal transcription
factors, such as TBP and TFIIH (35); therefore, it is likely that
components of the RNA polymerase II transcription complex
are also recruited to E2F target promoters. To examine these
possibilities, chromatin immunoprecipitation experiments
were performed using antibodies to E2Fs, pocket proteins, and
RNA polymerase II (Fig. 4). For these and the remaining
experiments, we chose to focus on the three clones which have
the highest levels of in vivo E2F binding, ChET 4, ChET 8, and
ChET 9. The data from the chromatin immunoprecipitation
experiment shown in Fig. 4 suggest that, similar to known E2F
binding sites, such as dhfr, the novel E2F binding sites also
FIG. 3. Genomic organization of the ChET clones. GenBank da-
tabase searches were performed with the sequences corresponding to
ChET 4, ChET 8, and ChET 9. After the locations of the clones were
determined, further Blast searches were performed examining the
sequences immediately adjacent to the cloned fragments. The loca-
tions of adjacent mRNAs are indicated by bent arrows. Positions of
consensus Sp1 (rectangles) and E2F (oval) sites are also shown.
FIG. 4. Characterization of the protein complexes bound in vivo to
the ChET clones. A chromatin immunoprecipitation experiment was
performed in HeLa cells utilizing antibodies (Ab) to E2F1 (lane 1),
E2F4 (lane 2), p107 (lane 3), p130 (lane 4), Rb (lane 5), RNA poly-
merase II (Pol II; lane 6), or no antibody as a control (lane 8). An
aliquot of the total input is also shown (lane 7). Primers to the ChET
clones or the DHFR promoter were used in PCRs for analysis.
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recruit pocket proteins. Interestingly, the binding profiles for
the pocket proteins observed at the three novel clones vary in
comparison to that observed at the dhfr promoter. The dhfr
promoter is bound mainly by p107 and p130, with very little
bound Rb, whereas the novel clones recruited almost equiva-
lent levels of the three pocket proteins. Because the use of
HeLa cells may have given altered pocket protein binding due
to the expression of the viral E7 protein, we also examined
pocket protein binding to the dhfr promoter and to the three
ChET clones in U937 cells. We found very similar recruitment
of pocket proteins to the E2F target promoters in the U937
cells and in HeLa cells (data not shown). In addition, the novel
E2F binding sites recruited RNA polymerase II, suggesting
that the three high-affinity clones indeed represent promoter
sequences.
We wished to further characterize a subset of the ChET
promoter clones. We chose the ChET 8 and ChET 9 clones for
an initial promoter analysis. If we are correct in assuming that
the ChET 8 clone represents the promoter for the KIAA0254
mRNA, then it should have promoter activity when inserted in
the correct orientation with the transcription start site up-
stream of the luciferase cDNA. The ChET 8 fragment was
cloned in both orientations (forward and reverse) upstream of
the luciferase cDNA and transfected into NIH 3T3 cells, and
promoter activity was measured. The cdc2 promoter-luciferase
reporter construct was used in these experiments as a positive
control. As shown in Fig. 5A, only the forward orientation of
the ChET 8 fragment showed high promoter activity, whereas
the reverse orientation did not. In fact, the ChET 8 promoter
was considerably more active than the cdc2 promoter, which is
a strong E2F-regulated promoter. Importantly, the orientation
of the ChET 8 fragment that showed promoter activity was the
correct orientation to drive KIAA0254 mRNA transcription.
We have previously shown that E2F site-containing promot-
FIG. 5. Transient-transfection analysis of ChET promoter-luciferase reporters. (A) A transient-transfection experiment in NIH 3T3 cells was
performed with a segment of ChET 8 cloned in either the forward or reverse orientation upstream of luciferase. The y axis of the graph represents
the relative luciferase units, with the transfected material shown on the x axis. pGL2 represents the luciferase vector lacking a promoter. (B) A
transient-transfection analysis was performed with the ChET 8 promoter-luciferase reporter transfected into NIH 3T3 cells in the presence of 2
g of an E2F1 expression vector (cytomegalovirus [CMV] E2F1) or the pCDNA3 vector as a control. The cdc2 promoter-luciferase reporter
construct was used as a control in both panels A and B. (C) Transient-transfection analysis of the ChET 9-luciferase reporter construct was
performed in NIH 3T3 cells. A graphical representation of the results is shown with the dhfr promoter used as a positive control. (D)
Overexpression of E2F1 upregulates ChET 9 promoter activity. Cotransfection experiments were performed containing 2 g of a CMV E2F1
expression construct with the ChET 9-luciferase construct or the dhfr-luciferase reporter vector as a control. Results of the luciferase assay are
shown in the graph as indicated for panel A.
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ers can be activated by cotransfection with E2F1 (25). To
determine if binding of E2F influences the transcriptional ac-
tivity of the ChET 8 promoter, we cotransfected the ChET 8
promoter-luciferase reporter construct with an E2F1 expres-
sion construct, again using cdc2-luciferase as a positive control
(Fig. 5B). We found that, as expected, E2F1 overexpression
activated the cdc2 promoter. In contrast, E2F1 repressed tran-
scription from the ChET 8 promoter. Although the exact
mechanism by which E2F1 represses the ChET 8 promoter is
still unknown, preliminary analyses indicate that squelching
(i.e., the sequestration of coactivators and/or general transcrip-
tion factors by a transactivation domain) is most likely not the
mechanism. For example, an E2F1 construct with the entire
transactivation domain deleted is still a potent repressor of
ChET 8 promoter activity (data not shown). The potential
relevance of these findings will be discussed further below (see
Discussion).
The ChET 9 fragment was also cloned into the luciferase
reporter vector for further analysis to determine if indeed this
cloned sequence contains promoter activity. A transient trans-
fection analysis of the ChET 9 luciferase reporter construct
demonstrated that the ChET 9 clone has promoter activity
(Fig. 5C) which is approximately equal to the activity of the
dhfr promoter (Fig. 5D). In addition, the overexpression of
E2F1 stimulates ChET 9 promoter activity (Fig. 5D). An ex-
tensive characterization of the ChET 9 promoter is in progress;
however, it is worth noting that deletion of the region contain-
ing the consensus E2F site eliminates the E2F1-mediated
transactivation (data not shown). These results indicate that
the ChET 9 clone has promoter activity and indeed contains an
E2F site which is functional in a transient overexpression sys-
tem.
Localization of potential E2F sites. Visual inspection of the
sequences corresponding to the three cloned promoter frag-
ments bound by E2F family members in vivo revealed that only
one clone, ChET 9, contains a consensus E2F site. Using a
computer program which has previously been shown to effec-
tively predict consensus E2F binding sites (21), we next exam-
ined the clones for matches to the E2F consensus sequence.
The cutoff previously used for identifying E2F sites was a 0.86
similarity to the consensus (21). Using this criterion, once
again the only clone containing a consensus E2F site was ChET
9. We thought that it might be possible to identify the E2F
binding sites within the ChET clones by using an in vitro assay.
Therefore, electromobility shift assays (EMSA) were per-
formed using the well-characterized E2F binding site in the
b-myb promoter as a probe. Two bands (complexes 1 and 2)
which represent specific protein-DNA complexes were ob-
served, as determined by antibody disruption (Fig. 6A) and
competition with the unlabeled probe (Fig. 6B); an additional
nonspecific band (complex 3) was also observed in most reac-
tions. Because each of the six E2Fs heterodimerizes with DP-1,
we used the DP-1 antibody to show that complex 2 contains an
E2F-DP heterodimer (Fig. 6A). Although complex 1 is specif-
ically competed by the probe (Fig. 6B), the DP-1 antibody did
not disrupt it. We (reference 24 and data not shown) and
others (41) have previously shown that a low-mobility complex
which binds specifically to E2F probes cannot be identified by
using antibodies to the different E2F family members. It is
possible that this complex represents an uncharacterized E2F
family member, or the epitope may be obscured by another
protein. To distinguish these possibilities, we employed anti-
bodies to the pocket proteins. However, antibodies to the
pocket proteins did not disrupt complex 1 (Fig. 6A). There-
fore, the identities of the proteins composing complex 1 are
still unknown.
There are no consensus E2F binding sites located in the
ChET 8 clone; therefore, it was not apparent which region was
responsible for the recruitment of E2F to the promoter region.
Because E2F sites are often found within 50 bp of the tran-
scription start site (21), we prepared a fragment which sur-
rounds the transcription start site for use as a competitor in an
EMSA competition experiment (Fig. 6B). Competition was
observed by using this promoter-proximal fragment; other re-
gions of the ChET 8 clone did not compete the probe (data not
shown). Further analyses will have to be performed to deter-
mine the exact location of the E2F site within the ChET 8
clone. Because competition was not complete in the in vitro
EMSA experiments, an alternative in vivo method for assaying
binding activity may need to be developed to localize the E2F
site within the cloned fragment. Although a complete muta-
tional analysis of the promoter region is beyond the scope of
this initial study, we have recently shown that the region re-
quired for responsiveness to E2F in the transient-expression
assay (Fig. 5B) resides in the promoter-proximal fragment
shown as a competitor in Fig. 6B (unpublished data).
EMSA competition experiments utilizing the oligonucleo-
tide corresponding to the consensus E2F site in the ChET 9
promoter revealed that this site is an efficient competitor of the
DP-E2F-DNA complex formed on the b-myb E2F site (Fig.
6B, lane 4). Interestingly, additional sequences located in other
regions of the ChET 9 fragment are required to compete
binding of complex 1 (Fig. 6B, lane 5). To confirm that E2F has
the ability to bind directly to the E2F site identified in ChET 9,
we performed EMSA experiments utilizing a radiolabeled
probe containing the E2F site located in ChET 9. As shown in
Fig. 6C, a single lower-mobility complex is detected when nu-
clear extract is incubated with the ChET 9 probe. The addition
of a DP-1 antibody to this reaction ablated the complex, indi-
cating that this complex contains a DP-1–E2F heterodimer.
Thus, the consensus site in ChET 9 competes binding to the
E2F site in the b-myb promoter and binds to a protein complex
which can be disrupted by a DP-1 antibody. Taken together
with the promoter-reporter assays, our results suggest that the
consensus E2F site in ChET 9 contributes to in vivo binding
and E2F responsiveness.
Characterization of expression patterns. Many E2F-regu-
lated promoters display cell cycle stage-specific transcription
patterns. However, almost without exception, the previously
identified E2F-regulated promoters were identified from a
pool of promoters already known to be cell cycle regulated
(42). It seemed possible that promoters identified by using an
unbiased approach might show different transcriptional regu-
lation. Therefore, we monitored the expression levels of the
mRNAs driven by ChET 4, ChET 8, and ChET 9 in a cell
differentiation system. U937 cells were forced to differentiate
by treating them with retinoic acid for 5 days, and then RNA
was prepared from log-phase (growing) and arrested (differ-
entiated) cells. As a control, we monitored the expression of
E2F1, an E2F-regulated gene that has been shown to be down-
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FIG. 6. In vitro EMSA of cloned fragments. In each panel (arrows), complex 3 represents a nonspecific band, complex 2 indicates an E2F-DP
complex, and complex 1 indicates a complex containing proteins that have not yet been identified. (A) Supershift EMSA was performed to
determine the components of the gel-shifted complexes. Reaction mixtures containing HeLa nuclear extract were incubated with an antibody (Ab)
to Sp1 (lane 2), DP-1 (lane 3), p130 (lane 4), p107 (lane 5), or Rb (lane 6) or no antibody (lane 1) followed by incubation with the b-myb E2F
site labeled as a probe. (B) EMSA competition experiments using the E2F site from the b-myb promoter as a probe. Oligonucleotides
corresponding to the unlabeled probe (lane 2), a fragment spanning the ChET 8 transcription start site (lane 3), an oligonucleotide corresponding
to the consensus E2F site from ChET 9 (lane 4), or the ChET 9 fragment (lane 5) were used as competitors. (C) EMSA using the ChET 9 E2F
site as a probe. A double-stranded oligonucleotide containing the consensus E2F site within the ChET 9 fragment (the sequence is shown in Fig.
3) was radiolabeled and used for EMSA. The probe was incubated with HeLa nuclear extract and the unlabeled probe (lane 3), a DP-1 antibody
(lane 4), or extract alone (lane 2). Lane 1 represents an aliquot of the probe without extract incubation. An arrow to the right of the gel image
indicates the specific E2F-DP complex.
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regulated when growing cells exit the cell cycle (14, 18, 32, 43).
As expected, levels of E2F1 mRNA decreased upon differen-
tiation and cell cycle arrest (Fig. 7A). In contrast, the levels of
mRNA for the three novel clones did not decrease significantly
in the U937 cell population upon differentiation, which sug-
gests that these promoters are not cell cycle regulated. These
data indicate that E2F family members may regulate both cell
cycle- and non cell cycle-responsive promoters. To determine
whether another unbiased approach would also yield con-
stitutively active E2F-regulated promoters, we examined the
mRNAs for two promoters that were predicted to be regulated
by E2F from a computer-assisted identification of consensus
E2F binding sites in the promoter regions. The large subunit of
RNAPII and XRCC2 were both identified in a previous study
which scanned the eukaryotic promoter databases for E2F
target promoters (21). Chromatin immunoprecipitation analy-
sis indicated that indeed the promoters for RNAPII large
subunit and XRCC2 are bound by E2F (data not shown).
Analysis of mRNA levels in the U937 cells indicated that one
of the two computer-identified genes was constitutively ex-
pressed whereas the other was downregulated upon differen-
tiation. Therefore, four of the five E2F-bound promoters iden-
tified by using unbiased approaches are not regulated upon
differentiation of U937 cells. It is also important to note that
although the amount of E2F1 declines during differentiation of
U937 cells, the overall amount of E2F activity remains high
due to the constitutive expression of E2F4. In fact, we have
shown that the amount of E2F4 bound to the ChET promoters
is unchanged after differentiation of U937 cells (data not
shown). Perhaps only those E2F target genes which are
uniquely responsive to E2F1 versus E2F4 will show a decline in
activity upon differentiation.
E2F target genes have been suggested to be critical regula-
tors of cell growth control. Therefore, we also examined
whether the expression of ChET 4, ChET 8, and ChET 9 is
altered during neoplastic transformation. We first compared
the levels of mRNAs in samples of human normal colon and
colon tumor taken from the same patient (Fig. 7B). In RT-
PCR analysis, ChET 4 had slightly higher levels of mRNA
expression in tumor tissue, ChET 8 showed a slight decrease in
mRNA levels in the tumor sample, and ChET 9 was signifi-
cantly upregulated in the colon tumor tissue. To determine if
FIG. 7. mRNA expression profiles of the three high-affinity ChET clones. (A) RT-PCR analysis of mRNA expression levels in RNA obtained
from either U937 log-phase (lane 1) or differentiated (diff; lane 2) cells. RT-PCR primers complementary to E2F1, ChET 9, ChET 8, ChET 4, RNA
polymerase (RNAP) II, or XRCC2 were used as indicated on the right. A water control is shown in lane 3. (B) RT-PCR analysis of RNA from
either normal (N) colon (lane 1) or colon tumor (T; lane 2). Primer sets to the specific mRNAs are indicated. (C) RT-PCR analysis of ChET 9
mRNA expression in the RNA obtained from either human normal colon (lane 1), colon tumor (lane 2), normal liver (lane 3), or liver tumor (lane
4). The normal colon and colon tumor samples are the same as those shown in panel B with GAPDH primers added as a loading control.
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upregulation of ChET 9 mRNA was specific to colon tumors,
we also compared normal liver and liver tumor mRNA levels.
To control for equivalent RNA sample concentrations, primers
for GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
were included in the reaction mixtures. The results show that
ChET 9 mRNA was upregulated in both tumor types (Fig. 7C),
which suggests that ChET 9 expression may be generally de-
regulated in human tumors. We have also confirmed that
ChET 9 mRNA is upregulated in eight of nine additional
human colon tumor samples (unpublished data).
DISCUSSION
To our knowledge, this is the first demonstration that the
chromatin immunoprecipitation assay can be used to clone
promoters which are direct in vivo targets of a mammalian
site-specific DNA binding protein. This provides a powerful
new approach to examine direct transcription factor targets in
an unbiased manner which does not rely on previous charac-
terization of a consensus sequence or a prior knowledge of
gene expression patterns. Although others have used similar
approaches to isolate genomic fragments (6, 36, 38), those
studies did not use subsequent experiments to confirm in vivo
binding of the factor of interest to the isolated DNA. Due to
this lack of in vivo confirmation, it is difficult to assess the
validity of the previous protocols. Also, sequence analysis of
the clones isolated in the previous studies indicated that the
cloned fragments corresponded to nonpromoter regions, such
as introns (5, 10, 22, 45, 46). One study did find that 3 out of 43
clones isolated after in vitro incubation of genomic DNA with
purified Ets-1 protein were promoters; however, the authors
did not confirm in vivo binding of ETS1 to these 3 clones or to
the other 40 isolated clones. Therefore, it is difficult to be sure
if any of the clones in that study were bona fide in vivo targets
of ETS1.
Utilizing the chromatin immunoprecipitation assay to clone
fragments bound by E2F family members, we found that 64%
(9 of 14) of the clones characterized were bona fide in vivo E2F
binding sites. Characterization of the three highest-affinity
clones revealed that they correspond to promoter regions (Fig.
8), providing validation that novel E2F-regulated promoters
can be isolated by using this protocol. Future studies will be
performed to determine whether any of the remaining clones
are promoters. A recent study using high-density microarray
analysis (31) found that about 7% of the mRNAs represented
on the microarray were responsive to overexpression of E2Fs.
These results suggest that a high percentage of mammalian
genes might be regulated by direct binding of E2F to the
promoter region. If this estimate of the number of E2F target
genes is correct, then it is not surprising that we did not isolate
one of the several dozen well-characterized E2F target pro-
moters in the set of nine positive clones that we analyzed.
However, one of our ChET clones (ChET 9, which corre-
sponds to the promoter region of the KIAA0160 gene) was
shown to be upregulated by E2F overexpression in the mi-
croarray analysis (31). The fact that this gene was isolated by
two independent screening methods for E2F target genes pro-
vides strong evidence that this promoter is indeed a direct
target of E2F family members and that the chromatin immu-
noprecipitation cloning technique can identify E2F-regulated
promoters.
One of the E2F4 clones, ChET 4, displayed high-affinity E2F
binding in vivo and corresponded to the promoter region for
the beclin 1 gene. Beclin 1 was isolated through its ability to
interact with bcl-2 and has been postulated to possess tumor
suppressor activity in breast cancer (1). It is interesting that the
gene for a potential tumor suppressor protein was isolated as
an E2F target gene because E2F regulation is thought to play
a significant role in tumorigenisis. Further experiments exam-
ining the nature of the role E2F plays in Beclin 1 regulation
may provide further insight into the role of E2F in tumor
development.
We found that two of the high-affinity E2F binding clones
did not contain E2F sites which closely matched the consensus
sequence. It is important to note that others have previously
shown that site-specific DNA binding proteins can regulate
transcription through sequence elements that diverge from the
consensus. For example, CREB, Ets-1, and AML1 can regulate
expression of the human T-cell receptor beta chain promoter
through nonconsensus binding sites (12) and a nonconsensus
site mediates regulation of the atrial natriuretic factor by se-
rum response factor (13). Computer inspection suggests that
the ChET clones may contain multiple low-affinity E2F sites,
each of which diverges from the known consensus. Perhaps a
combination of weak binding sites allows for cooperative re-
cruitment of the E2F complex in vivo. It is also possible that
the promoter context may greatly influence E2F binding effi-
ciency within the cellular environment. We have previously
shown that some (e.g., CCAAT and YY1) but not all (e.g.,
Oct1, Ap2, and NF1) transcription factor sites can synergize
with E2F sites to activate transcription (47). It is possible that
this synergy was mediated by cooperative DNA binding. Also,
others have shown that Sp1 can physically interact with E2F
family members and that binding of Sp1 can influence the
occupancy of a nearby E2F site (20, 27). Each of the three
characterized ChET clones contains at least one consensus Sp1
binding site (Fig. 3). Finally, others have shown that E2Fs can
interact with other sequence-specific DNA binding proteins,
FIG. 8. Summary of information obtained relating to the ChET
promoter clones.
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such as C/EBP (17, 44). Interestingly, we have recently shown
that E2F1 can be recruited to promoters which contain
C/EBP binding sites but lack E2F consensus sites (Graveel
and Farnham, unpublished). It remains to be determined if
C/EBP and/or other protein-protein interactions are mediat-
ing the recruitment of E2F to the promoters we have cloned.
However, recruitment of E2F through the recognition se-
quence of another DNA binding protein could explain why
some of the cloned fragments failed to show robust competi-
tion of a consensus E2F site in vitro.
To date, the majority of well-characterized E2F target pro-
moters have been shown to be cell cycle regulated and acti-
vated by E2F overexpression. In contrast, our three novel E2F
target promoters are constitutively expressed in growing versus
differentiated U937 cells. It is perhaps not surprising that E2F
target promoters isolated using an unbiased approach show
expression profiles different from those of the well-character-
ized E2F target promoters. According to microarray analyses,
hundreds of genes are regulated by E2F family members (16,
31). It is highly unlikely that this large number of mRNAs,
which encode proteins having highly diverse biological func-
tions, will all show exactly the same expression pattern in all
cell types.
It is interesting that the mRNA produced by each of the
three novel promoters displayed unique expression profiles
when normal versus tumor human primary samples were ex-
amined; one mRNA was constitutively expressed, one mRNA
was downregulated in the tumor sample, and one mRNA was
highly upregulated in tumor RNA. Interestingly, one of the
promoters that we cloned which displayed high-affinity binding
in vivo was shown to be repressed, not activated, by E2F1.
Although most E2F target genes studied to date are activated
in response to overexpression of E2F1, it has been shown that
the cyclin D1 promoter is also repressed by E2F1 (48). In
addition, the recent microarray analysis by Muller et al. pro-
vided evidence that E2Fs can both activate and repress cellular
genes, although their data did suggest that most E2F-mediated
repression was indirect (31). Additional evidence supporting
E2F-mediated repression of the ChET 8 promoter can be
extrapolated from a recent study examining the cell cycle fluc-
tuations of thousands of human mRNAs (4). We have ex-
tracted the expression profiles of E2F1 and KIAA0254, the
mRNA driven by the ChET 8 promoter, from the published
microarray data. Interestingly, ChET 8 mRNA levels are in-
versely related to E2F1 mRNA levels (data not shown). Col-
lectively, these findings support a role for E2F1 in repression of
the ChET 8 promoter. Further experiments need to be per-
formed to characterize similarities and differences between the
promoters which are directly activated and those which are
directly repressed upon overexpression of E2F1. However,
these observations suggest that the nature and context of the
E2F binding site may influence the role that E2F plays in
regulation of a promoter.
In summary, the data presented in this paper establish the
basis for cloning novel promoters regulated by specific tran-
scription factors through chromatin immunoprecipitation tech-
niques. Our initial data suggest that the E2F consensus binding
sequence may not account for all potential in vivo E2F targets,
possibly due to the roles of interacting proteins within the
cellular environment. Importantly, the possibility that E2F
family members can regulate promoters that lack consensus
binding sites may aid in the understanding of microarray stud-
ies which show that hundreds of mRNAs can respond to over-
expression of E2Fs (16, 31). Also, we find it most interesting
that the expression profiles of the genes identified by using this
unbiased approach are quite different from the expression pro-
files of the previously characterized E2F target genes. Finally,
of particular interest are ChET 9 and ChET 4. ChET 9 con-
tains a consensus E2F binding site and shows high-affinity
binding in vivo and in vitro. Interestingly, the KIAA0160
mRNA which is transcribed by ChET 9 is upregulated in two
different tumor types. The protein encoded by the KIAA0160
mRNA has high homology to a Drosophila protein called
Su(z)12. This protein was isolated as a suppressor of a muta-
tion of the gene for zeste, a site-specific DNA binding tran-
scription factor. Although no characterizations of Su(z)12 have
been performed; another suppressor of zeste, Su(z)2, is known
to be a locus-specific chromosome binding protein. Therefore,
it is possible that KIAA0160 will be involved in transcriptional
regulation. ChET 4, which shows high-affinity E2F in vivo
binding but does not contain a consensus E2F site, is the
promoter region for the beclin 1 gene, a putative tumor sup-
pressor gene. The Beclin 1 protein is thought to effect the
degradation of cellular proteins and has been shown to be
significantly downregulated in human breast carcinomas (26).
Our future studies will be focused on understanding the role of
Beclin 1 and KIAA1060 in neoplastic transformation.
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